Chia Tai Qingchunbao Pharmaceutical Co., Ltd.

To evaluate the efficacy and safety of sodium salvianolic acid A for injection in myocardial protection in patients with acute myocardial infarction after PCI

To observe the plasma flunarizine concentrations of flunarizine capsules (test preparation) and flunarizine capsules (trade name: Sibelium, reference preparation) in Chinese healthy subjects after single oral administration in fasting/postprandial state. The pharmacokinetic parameters of flunarizine were used as endpoint evaluation indicators to evaluate whether the test preparation and the reference preparation are equivalent preparations, and to assess the safety of the test preparation and the reference preparation.

1. To evaluate the tolerability, safety and pharmacokinetic characteristics of single-dose sodium salvianolic acid A for injection in healthy subjects, and to investigate the effects of two solvents; 2. To evaluate the tolerability, safety and pharmacokinetic characteristics of multiple-dose sodium salvianolic acid A for injection in healthy subjects, and to preliminarily evaluate the pharmacodynamics; 3. To investigate the incidence of positive skin test results of sodium salvianolic acid A for injection.